Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02113917
Other study ID # NI10015
Secondary ID AOM 10219
Status Completed
Phase
First received
Last updated
Start date January 2010
Est. completion date January 12, 2017

Study information

Verified date November 2021
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Different study of HLHa patients : - Diagnosis criteria, because criteria are based on pediatric genetic studies. - Physiopathological studies: genetic studies have demonstrated the role of CD8+ cells, in particular because they have a genetic defect affecting their cytotoxic functions in HLH pediatric. the aim is to establish if the same defect is found in both some or in all of HLHa patients. If this is the case, to then establish whether hypomorphic genetic mutations are responsible.


Description:

Formation of a prospective and retrospective infant, adolescent and adult HLH patients cohort. Collection of clinical and biological, therapeutics, informations, in a register, The collection of information is: - To identify clinical and biological criteria specific to HLHa - Classify patients into homogeneous groups, based on clinical biological scalability in particular, with regards to their response to treatment - Identify and analyze the behavioral therapy Creation of a bank of biological samples for use in the study of the pathophysiology of HLHa. Background: The hemophagocytic syndrome in infant, adolescent and adults (HLH) is a serious and often lethal condition. The study of literature series HLHa shows that these syndromes frequently develop in immunocompromised patients (renal transplant, HIV, collagen in Processing immunosuppressants) in the course of a viral infection. HLH syndrome has also been described as a clinical form of lymphoma or connective disease (lupus). These clinical forms are rare, severe and recurrent suggesting the possibility that immune deficiency could be involved. The study of pediatric forms has definitely established a link between HLH syndrome and the presence of immune deficiency by identifying the nature of the latter. Four genetically determined diseases are manifested by HLH syndrome. These conditions are Family lymphohistiocytosis (LHF) syndrome, Chediak-Higashi CHS syndrome, Griscelli (GS) type 2 syndromes and X-linked lymphoproliferative (XLP 1 and 2). The mutated genes are respectively perforin Unc 13.4 and syntaxin in the LHF2, 3, 4 (10q locus genetic for LHF 1), CHS1/LYST (Lysosomal Trafficking regulator) in the CHS, in the Rab27a GS type 2, and XIAP and SH2D1A in the XLP. It is now well established that proteins encoded by these genes are necessary for the cytotoxic function of CD8 + and in the absence of these proteins is the cytotoxocity CD8 + deficient. Also, closed clinical and biological characteristics shared by pediatric genetic and adult forms suggest the existence of immune defects responsible for some or all HLH adult patients.


Recruitment information / eligibility

Status Completed
Enrollment 204
Est. completion date January 12, 2017
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria: Major criteria: - hemophagocytosis found in a specimen histology. - Fever - Splenomegaly Minor criteria: - adenopathy - cytopenia> 2 cell lines Hemoglobin <9 g / dl (less than 4 weeks and> 12 g / dl) Platelets <100 000 x 10 / l Neutrophils <1 10 / l - hypertriglyceridaemia and / or hypofibrinogenaemia Elevated triglycerides> 3 mmol / l Fibrinogen <1.5 g / l - Ferritin> 500 microg / L These criteria will be those used for the diagnosis of HLH in adults: One major criterion and two minor (including hyper ferritin or hypertriglyceridemia) 3 minor criteria (including hyper ferritin or hypertriglyceridemia) Exclusion Criteria: - Pregnant women - A person under guardianship - Patients under the age of 2 years

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Identification of biological markers


Locations

Country Name City State
France Clinical Research Unit Paris

Sponsors (3)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris Laboratory of normal and pathological development Immune System - IFR 94 U768, Reference Centre for Hereditary Immunodeficiency: CEREDIH

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary biologicals criteria measure of : cytokines expression (mmol/L) Hemoglobin (g/dl) number of Platelets (number/L) number of Neutrophils (number/L) number of triglycerides (mmol/L) number of fibrinogen (g/L) number of Ferritin (microg/L) T0 (before traitment
Primary name of treatment administrated treatments T2 (T2 is the first day of treatment)
Primary Clinicals criteria clinicals description of patients : Fever, Splenomegaly and adenopathy T0
Primary biologicals criteria measure of : cytokines expression Hemoglobin level number of Platelets number of Neutrophils number of triglycerides> number of fibrinogen number of Ferritin T1 (T1 is the first day of HLH syndrome)
Primary biologicals criteria measure of : cytokines expression Hemoglobin level number of Platelets number of Neutrophils number of triglycerides> number of fibrinogen number of Ferritin T2 (T2 is the first day of treatment)
Primary biologicals criteria measure of : cytokines expression Hemoglobin level number of Platelets number of Neutrophils number of triglycerides> number of fibrinogen number of Ferritin T4 (6 /12 months after the resolution of HLH)
Primary Clinicals criteria clinicals description of patients : Fever, Splenomegaly and adenopathy T1(T1 is the first day of HLH syndrome)
Primary Clinicals criteria clinicals description of patients : Fever, Splenomegaly and adenopathy T2 (T2 is the first day of treatment)
Primary Clinicals criteria clinicals description of patients : Fever, Splenomegaly and adenopathy T4 6 /12 months after the resolution of HLH)
Primary name of treatment administrated treatments T4(6/12 month after resolution of HLH)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01494103 - Administration of Donor T Cells With the Caspase-9 Suicide Gene Phase 1
Recruiting NCT04999878 - A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome. Phase 4
Recruiting NCT05882175 - Prospective Validation of the OHI Index
Not yet recruiting NCT05353179 - Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers Early Phase 1
Not yet recruiting NCT04500886 - Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome N/A
Recruiting NCT05936086 - A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH N/A